# Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

> **NCT03984760** · PHASE3 · COMPLETED · sponsor: **Panion & BF Biotech Inc.** · enrollment: 240 (actual)

## Conditions studied

- Hyperphosphatemia
- End Stage Renal Disease
- ESRD

## Interventions

- **DRUG:** Ferric Citrate
- **DRUG:** Sevelamer Carbonate

## Key facts

- **NCT ID:** NCT03984760
- **Lead sponsor:** Panion & BF Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-19
- **Primary completion:** 2021-02-20
- **Final completion:** 2021-02-20
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2021-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03984760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03984760, "Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03984760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*